If you have been reading about quality control and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
=== Young Investigator (YI) Post-Doctoral Programme === (RCB-YI award) has been initiated to nurture outstanding recent PhDs with innovative ideas and the drive to pursue novel discoveries under the mentorship of RCB faculty. RCB-YI award has been instituted for both Indian and Foreign nationals on the competitive basis with initial appointment for three years which is extendable on rigorous review for additional two years.
One-color light is well suited for traffic lights and signals, exit signs, emergency vehicle lighting, ships' navigation lights, and LED-based Christmas lights. Because of their long life, fast switching times, and visibility in broad daylight due to their high output and focus, LEDs have been used in automotive brake lights and turn signals. The use in brakes improves safety, due to a great reduction in the time needed to light fully, or faster rise time, about 200 milliseconds faster than an incandescent bulb. This gives drivers behind more time to react. In a dual intensity circuit (rear markers and brakes) if the LEDs are not pulsed at a fast enough frequency, they can create a phantom array, where ghost images of the LED appear if the eyes quickly scan across the array. White LED headlamps are beginning to appear. Using LEDs has styling advantages because LEDs can form much thinner lights than incandescent lamps with parabolic reflectors. Due to the relative cheapness of low output LEDs, they are also used in many temporary uses such as glowsticks and throwies. Artists have also used LEDs for LED art.
The GTP-binding domain is conserved in both EF-1alpha/EF-Tu and also in EF-2/EF-G and thus seems typical for GTP-dependent proteins which bind non-initiator tRNAs to the ribosome. The GTP-binding translation factor family also includes the eukaryotic peptide chain release factor GTP-binding subunits and prokaryotic peptide chain release factor 3 (RF-3); the prokaryotic GTP-binding protein lepA and its homologue in yeast (GUF1) and Caenorhabditis elegans (ZK1236.1); yeast HBS1; rat Eef1a1 (formerly "statin S1"); and the prokaryotic selenocysteine-specific elongation factor selB.
Sources: en.wikipedia.org
=== Apples to cider === An important component in cider-making is the addition of sulfur dioxide to inhibit the growth of many spoilage bacteria or yeasts in the juice. This encourages the inoculated yeast to dominate the juice environment, converting sugars to alcohol. Once sulfur dioxide dissolves in the juice, it converts into a pH dependent mixture of bisulfite, sulfite ions, and molecular sulfur dioxide. The "unbound" sulfur dioxide provides the antimicrobial environment in the juice, while the bisulfite and sulfite ions contribute to flavour. The quantity of sulfur dioxide needed to inhibit microbial activity is directly related to the pH of the juice; lower pH means less should be added, while higher pH juice requires more. Many cider producers add sulfur dioxide immediately after pressing and juicing, but before fermentation. However, in some cases it can be added afterwards to act as an antioxidant or stabiliser. This prevents the finished cider from releasing hydrogen peroxide or aldehydes that produce "off" odors and flavours. Nitrogen is also a very important nutrient supporting yeast growth and fermentation in cider. Yeast require different forms of nitrogen to take up and use themselves so nitrogenous compounds are often added to apple juice. The mixture of nitrogen-containing compounds that yeast can use are referred to as 'Yeast Assimilable Nitrogen', or YAN.
=== Legal status === Avutometinib/defactinib was approved for medical use in the United States in May 2025. The FDA granted the application for avutometinib/defactinib priority review, breakthrough therapy, and orphan drug designations.
During the socialist era in Yugoslavia, the only legal political parties were the three branches of the federal League of Communists of Yugoslavia (SKJ): League of Communists of Serbia (SKS), League of Communists of Vojvodina (SKV) and League of Communists of Kosovo (SKK). The Serbian branch remained relatively stable and loyal to the federal party until the late 1980s, when it became split over what action to take in Kosovo when protests and fights broke out between ethnic Albanians and Serbs. The more traditional Communists supported President Ivan Stambolić, who advocated continued neutrality as a means to solve the dispute; while more radical and nationalist-leaning members supported Slobodan Milosević, who advocated the protection of Kosovo Serbs, who had claimed that their population was being pressured to leave Kosovo by Albanian separatists. Milosević utilized public sentiment and opposition to Kosovo Albanian separatism to rally large numbers of supporters to help him overthrow the Communist leadership in Vojvodina, Kosovo and the Socialist Republic of Montenegro in what was known as the anti-bureaucratic revolution. Afterwards, the Serbian League of Communists selected Milosević as its leader. Milosević took a hard stand on Albanian nationalism in Kosovo and pressured the Yugoslav government to give him emergency powers to deal with Kosovo Albanian separatists. Furthermore, he reduced the autonomy of the autonomous provinces of Kosovo and Vojvodina and installed politicians loyal to him to serve as their representatives.
Sources: en.wikipedia.org
==== Odd atomic number ==== 53 stable nuclides have an even number of protons and an odd number of neutrons. They are a minority in comparison to the even-even isotopes, which are about 3 times as numerous. Among the 41 even-Z elements that have a stable nuclide, only two elements (argon and cerium) have no even-odd stable nuclides. One element (tin) has three. There are 24 elements that have one even-odd nuclide and 13 that have two odd-even nuclides. Of 35 primordial radionuclides there exist four even-odd nuclides (see table at right), including the fissile 23592U. Because of their odd neutron numbers, the even-odd nuclides tend to have large neutron capture cross-sections, due to the energy that results from neutron-pairing effects. These stable even-proton odd-neutron nuclides tend to be uncommon by abundance in nature, generally because, to form and enter into primordial abundance, they must have escaped capturing neutrons to form yet other stable even-even isotopes, during both the s-process and r-process of neutron capture, during nucleosynthesis in stars. For this reason, only 19578Pt and 94Be are the most naturally abundant isotopes of their element. 48 stable odd-proton-even-neutron nuclides, stabilized by their paired neutrons, form most of the stable isotopes of the odd-numbered elements; the very few odd-proton-odd-neutron nuclides comprise the others. There are 41 odd-numbered elements with Z = 1 through 81, of which 39 have stable isotopes (technetium (43Tc) and promethium (61Pm) have no stable isotopes).
=== Pharmacokinetics === Loratadine when given orally, is well absorbed from the gastrointestinal tract, and has rapid first-pass hepatic metabolism; it is metabolized by isoenzymes of the cytochrome P450 system, including CYP3A4, CYP2D6, and, to a lesser extent, several others. Loratadine is almost totally (97–99%) bound to plasma proteins. Its metabolite desloratadine, which is largely responsible for the antihistaminergic effects, binds to plasma proteins by 73–76%. Loratadine's peak effect occurs after 1–2 hours, and its biological half life is on average eight hours (range 3 to 20 hours) with desloratadine's half-life being 27 hours (range 9 to 92 hours), accounting for its long-lasting effect. About 40% is excreted as conjugated metabolites into the urine, and a similar amount is excreted into the feces. Traces of unmetabolised loratadine can be found in the urine. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.
6 October An open source platform to match genomically profiled cancer patients to precision medicine drug trials is reported. Neuroscientists report PFC-Hb connectivity white matter impairment in both cocaine and heroin addiction. 7 October News outlets report about a study published on 28 September theorizing that the supercontinent Amasia will form within 300 million years when the Pacific Ocean closes. Neuroscientists report experimental MRI results that so far appear to imply nuclear proton spins of 'brain water' in the brain were entangled, suggesting brain functions that operate non-classically which may support quantum mechanisms being involved in consciousness as the signal pattern declined when human participants fell asleep. 8 October – Researchers report recommendations concerning potential geopolitical implications of potential future information about or from extraterrestrial intelligence.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.